A Study on Neoadjuvant Therapy for Her-2 Positive Breast Cancer and the Prognosis by Detecting CTCs
Status:
Unknown status
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
Docetaxel plus carboplatin and trastuzumab has been a standard treatment for patients with
human epidermal growth factor receptor-2（HER-2）positive. The investigators witnessed a higher
pathological complete remission(pCR) rate but no obvious increase in cardiac toxicity when
used the anthracycline instead of carboplatin. The investigators expect to carry out a large
sample size clinical research to optimize the existing therapeutic regimen
Phase:
Phase 2
Details
Lead Sponsor:
Hospital Affiliated to Military Medical Science, Beijing